Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaled antibiotic shows promise for ventilator lung infections

NCT ID NCT07369336

Disease control Sponsor: Postgraduate Medical Institute, Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding an inhaled antibiotic (amikacin) to standard treatment helps ICU patients recover faster from ventilator-associated pneumonia. Researchers tracked how quickly the infection cleared, how long patients needed the ventilator, and any side effects. The trial included 90 adults aged 18-80 who were on ventilators and diagnosed with VAP.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

90 people

The number who actually took part.

Started

Jan 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion Criteria Participants must meet all of the following: 1. Age 18-80 years 2. Currently receiving invasive mechanical ventilation 3. Clinical diagnosis of ventilator-associated pneumonia (VAP) based on: New or progressive infiltrate on chest imaging and at least two of the following: Fever \> 38°C or hypothermia \< 36°C Leukocytosis \>12,000 or leukopenia \<4,000 cells/µL Increased purulent respiratory secretions Worsening oxygenation indices 4. Initiation of systemic IV antibiotics for VAP 5. Availability of baseline respiratory sample for culture 6. Informed consent obtained from patient's legal guardian/attendantExclusion Criteria Any of the following will lead to exclusion: 1. Known hypersensitivity to aminoglycosides (e.g., amikacin) 2. Chronic kidney disease Stage 4-5 or baseline serum creatinine \>2 mg/dL 3. Pre-existing hearing loss or vestibular dysfunction 4. Severe bronchospasm or airway instability preventing safe nebulization 5. VAP due to confirmed pan-resistant microorganisms requiring alternative therapy Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventilator-associated pneumonia (VAP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ventilator-associated pneumonia (VAP)

Contacts and locations

Locations

  • Lahore General Hospital

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.